These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 28233270

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Specific Lipoprotein(a) apheresis attenuates progression of carotid intima-media thickness in coronary heart disease patients with high lipoprotein(a) levels.
    Ezhov MV, Safarova MS, Afanasieva OI, Pogorelova OA, Tripoten MI, Adamova IY, Konovalov GA, Balakhonova TV, Pokrovsky SN.
    Atheroscler Suppl; 2015 May; 18():163-9. PubMed ID: 25936321
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Primary and secondary prevention of cardiovascular disease in patients with hyperlipoproteinemia (a).
    Grützmacher P, Öhm B, Szymczak S, Dorbath C, Brzoska M, Kleinert C.
    Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):22-26. PubMed ID: 28233269
    [Abstract] [Full Text] [Related]

  • 7. Lipoprotein apheresis for Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease--Additional particular aspects of the Pro(a)LiFe multicenter trial.
    Klingel R, Heibges A, Fassbender C.
    Atheroscler Suppl; 2015 May; 18():35-40. PubMed ID: 25936302
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The German Lipoprotein Apheresis Registry (GLAR) - almost 5 years on.
    Schettler VJJ, Neumann CL, Peter C, Zimmermann T, Julius U, Roeseler E, Heigl F, Grützmacher P, Blume H, Vogt A, Scientific Board of GLAR for the German Apheresis Working Group.
    Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):44-49. PubMed ID: 28233268
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Differences in the atherogenic risk of patients treated by lipoprotein apheresis according to their lipid pattern.
    von Dryander M, Fischer S, Passauer J, Müller G, Bornstein SR, Julius U.
    Atheroscler Suppl; 2013 Jan; 14(1):39-44. PubMed ID: 23357139
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Lipoprotein apheresis in Austria - Reduction of cardiovascular events by regular lipoprotein apheresis treatment.
    Berent T, Derfler K, Berent R, Sinzinger H.
    Atheroscler Suppl; 2019 Dec; 40():8-11. PubMed ID: 31818453
    [Abstract] [Full Text] [Related]

  • 18. Lipoprotein Apheresis for Lipoprotein(a)-Associated Cardiovascular Disease: Prospective 5 Years of Follow-Up and Apolipoprotein(a) Characterization.
    Roeseler E, Julius U, Heigl F, Spitthoever R, Heutling D, Breitenberger P, Leebmann J, Lehmacher W, Kamstrup PR, Nordestgaard BG, Maerz W, Noureen A, Schmidt K, Kronenberg F, Heibges A, Klingel R, Pro(a)LiFe-Study Group.
    Arterioscler Thromb Vasc Biol; 2016 Sep; 36(9):2019-27. PubMed ID: 27417585
    [Abstract] [Full Text] [Related]

  • 19. Kinetics of Lipoprotein(a) in patients undergoing weekly lipoprotein apheresis for Lp(a) hyperlipoproteinemia.
    Tselmin S, Müller G, Schatz U, Julius U, Bornstein SR, Hohenstein B.
    Atheroscler Suppl; 2017 Nov; 30():209-216. PubMed ID: 29096840
    [Abstract] [Full Text] [Related]

  • 20. Hyperlipoproteinaemia(a) - apheresis and emerging therapies.
    Vogt A.
    Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):12-17. PubMed ID: 28185213
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.